The quest to cure chronic hepatitis B has largely stalled on a fundamental challenge: how to clear infected liver cells without causing dangerous liver damage. Current treatments suppress viral replication but rarely eliminate the infection entirely, leaving patients dependent on lifelong therapy. A new mechanism analysis of the experimental drug bepirovirsen suggests it may solve this dilemma by precisely targeting infected hepatocytes for immune destruction.
Analyzing blood samples from 82 participants in the B-Together trial, researchers tracked molecular changes as patients received bepirovirsen alongside standard nucleoside analogs. The drug activated immune effector pathways within three weeks, followed by increased expression of genes associated with immune cell proliferation and activation by week five. Most significantly, by week eight, blood markers showed elevated liver-specific and apoptotic proteins, indicating systematic hepatocyte death. This cellular destruction correlated strongly with temporary ALT spikes—a marker of liver inflammation—and was most pronounced in patients who achieved viral surface antigen declines.
This represents a potentially paradigm-shifting approach to hepatitis B cure. Unlike current antivirals that merely suppress replication, bepirovirsen appears to orchestrate targeted immune clearance of infected cells—the holy grail of functional cure strategies. The transient ALT elevations, initially concerning as potential liver toxicity, now appear to be therapeutic signals of infected cell elimination. However, the narrow therapeutic window between effective clearance and harmful liver damage remains the critical safety question. With over 290 million people chronically infected worldwide, confirming this mechanism could transform hepatitis B from a lifelong condition into a curable infection.